Domarkas Juozas, Dudouit Fabienne, Williams Christopher, Qiyu Qiu, Banerjee Ranjita, Brahimi Fouad, Jean-Claude Bertrand Jacques
Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/ Royal Victoria Hospital, Montreal, H3A1A1, Quebec, Canada.
J Med Chem. 2006 Jun 15;49(12):3544-52. doi: 10.1021/jm0600390.
According to the "combi-targeting" concept, the EGFR tyrosine kinase (TK) inhibitory potency of compounds termed "combi-molecules" is critical for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2. Here we report on the optimization of the EGFR TK inhibitory potency of the combi-molecules of the nitrosourea class by comparison with their aminoquinazoline and ureidoquinazoline precursors. This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the nitrosoureido moiety of the synthesized drugs. Compounds (3'-Cl and Br series) with small angles (0.5-3 degrees ) were generally stronger EGFR TK inhibitors than those with large angles (18-21 degrees ). This was further corroborated by ligand-receptor van der Waals interaction calculations that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR. Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC(50) values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-tranfected cell line (Pearson r = 0.8). On the basis of stability (t(1/2)), EGFR TK inhibitory potency (IC(50)), and selective erbB2 targeting, compound 23, a stable nitrosourea, was considered to have the structural requirements for further development.
根据“联合靶向”概念,被称为“联合分子”的化合物对表皮生长因子受体(EGFR)酪氨酸激酶(TK)的抑制效力,对于选择性抑制EGFR或其最接近的家族成员erbB2表达紊乱的肿瘤细胞生长至关重要。在此,我们通过与其氨基喹唑啉和脲基喹唑啉前体进行比较,报告了亚硝基脲类联合分子的EGFR TK抑制效力的优化情况。这导致发现了一个影响其EGFR TK抑制效力的新结构参数,即喹唑啉环平面与合成药物的脲基或亚硝基脲基部分之间的扭转角。扭转角小(0.5 - 3度)的化合物(3'-氯和溴系列)通常比扭转角大(18 - 21度)的化合物是更强的EGFR TK抑制剂。配体 - 受体范德华相互作用计算进一步证实了这一点,该计算表明在EGFR狭窄的ATP裂隙中,大扭转角会造成显著的结合阻碍。在一对小鼠成纤维细胞NIH3T3细胞中进行的选择性抗增殖研究表明,其中一个NIH3T3/neu细胞转染了erbB2癌基因,抑制EGFR TK的IC(50)值可以很好地预测它们对erbB2转染细胞系血清刺激生长的选择性效力(皮尔逊相关系数r = 0.8)。基于稳定性(t(1/2))、EGFR TK抑制效力(IC(50))和选择性erbB2靶向性,化合物23(一种稳定的亚硝基脲)被认为具有进一步开发的结构要求。